{
    "brief_title": "This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant \u00b1 Goseraline Versus Placebo Combined With Fulvestrant \u00b1 Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",
    "phase": "Phase 3",
    "drugs": "['FCN-437c,Fulvestrant,Goserelin acetate', 'Placebo,Fulvestrant,Goserelin acetate']",
    "drugs_list": [
        "FCN-437c,Fulvestrant,Goserelin acetate",
        "Placebo,Fulvestrant,Goserelin acetate"
    ],
    "diseases": "['Advanced Breast Cancer', 'Female Breast Cancer']",
    "diseases_list": [
        "Advanced Breast Cancer",
        "Female Breast Cancer"
    ],
    "enrollment": "312.0",
    "inclusion_criteria": "inclusion criteria: \n\n Patients must meet all of the following conditions: \n\n Female advanced breast cancer patients aged \u226518 years, diagnosed as HR+ HER2-. HR+ positive is defined as\uff1aHistological and/or cytological confirmed ER+, PR + or -, defined as immunohistochemistry showing positive nuclear staining of estrogen/progesterone receptor tumor cells\u22651%\uff1b HER2-negative is defined as\uff1aHistological and/or cytological confirmed HER2-\uff0c defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+,the ISH test result must be negative\u3002 \n\n Arbitrary menopausal status.Postmenopausal female is defined as: \n\n After bilateral oophorectomy ; Age\u226560 years Age<60 years and menopause for more than 1 year without chemotherapy and treatment with tamoxifen, toremifene and ovarian function suppression, while blood FSH and estradiol levels meet the postmenopausal range and for postmenopausal patients who are taking tamoxifen or toremifene and who are younger than 60 years old, continuous detection of serum FSH and estradiol levels must meet the postmenopausal range.. \n\n Previous treatment criteria: Second-line and above patients can be included in the group\u3002 \n\n Previous treatment criteria: Second-line and above patients can be enrolled. Eastern cooperative oncology group (ECOG) 0-1\u3002 \n\n According to the RECIST 1.1 criteria, patients must have at least one measurable lesion, or patients with only bone metastases, if no measurable lesions are present, must have at least one bone lesion predominantly lytic. \n\n Note:If the lesion has received radiotherapy or other locoregional treatment, there must be imaging evidence of disease progression in the lesion after completion of treatment, and the lesion can be considered as a measurable lesion. For patients with no measurable lesion and only one osteolytic lesion, if the lesion was previously treated with radiotherapy, imaging evidence is needed to show the progression of bone lesions after radiotherapy.\u3002 \n\n Life expectancy is not less than 12 weeks; \n\n Adequate bone marrow and organ function: \n\n Absolute neutrophil count (ANC) \u22651.5 x 109/L \n\n Hemoglobin \u226590 g/dL(no red blood cell infusion within 14 days before randomization) \n\n Platelet count \u226590 x 109/L \n\n Total serum bilirubin \u2264 1.5 X upper limit of normal (ULN) , total serum bilirubin\u22643 x ULN in patients with Gilbert syndrome; \n\n Aspartate aminotransferase (AST)and alanine aminotransferase (ALT) \u22642.5x ULN; for patients with liver metastases,both AST and ALT \u22645\u00d7 ULN; \n\n Creatinine <1.5 \u00d7 ULN or creatinine clearance\u226550 mL / min[Ccr = ((140- age) \u00d7body weight (kg)) / (72\u00d7 Scr (mg / dl)) or Ccr = ((140-age)\u00d7 body weight (kg)) / (0.818\u00d7 Scr (umol / L)) Note: Females were calculated \u00d70.85] \n\n QTcF < 470 ms \uff1b \n\n The patient is willing and able to comply with planned visits, treatment plans, laboratory examinations, and other trial procedures\u3002 \n\n The patient is fully aware of the study and has signed an informed consent form (ICF); \n\n For perimenopausal/premenopausal patients only: a high-efficiency contraceptive method with a failure rate of less than 1% per year must be used with a partner throughout the study period and for at least 90 days after discontinuation. \n\n ",
    "exclusion_criteria": ": \n\n Patients who meet any of the following conditions are not allowed to enter this clinical study\uff1a \n\n The ",
    "brief_summary": "This is a multicenter, randomized, double-blind, placebo-controlled Phase iii clinical study evaluating the efficacy and safety of FCN- 437c in combination with fluvestrant \u00b1 goseraline versus placebo in combination with fluvestrant \u00b1 goseraline in women with HR+ and HER2- advanced breast cancer.",
    "NCT_ID": "NCT05438810"
}